0001062993-16-011985.txt : 20161103 0001062993-16-011985.hdr.sgml : 20161103 20161103070847 ACCESSION NUMBER: 0001062993-16-011985 CONFORMED SUBMISSION TYPE: 6-K PUBLIC DOCUMENT COUNT: 3 CONFORMED PERIOD OF REPORT: 20161103 FILED AS OF DATE: 20161103 DATE AS OF CHANGE: 20161103 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Trillium Therapeutics Inc. CENTRAL INDEX KEY: 0001616212 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 000000000 STATE OF INCORPORATION: A6 FISCAL YEAR END: 1214 FILING VALUES: FORM TYPE: 6-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-36596 FILM NUMBER: 161970126 BUSINESS ADDRESS: STREET 1: 2488 DUNWIN DRIVE CITY: MISSISSAUGA STATE: A6 ZIP: L5L 1J9 BUSINESS PHONE: (416) 595-0627 MAIL ADDRESS: STREET 1: 2488 DUNWIN DRIVE CITY: MISSISSAUGA STATE: A6 ZIP: L5L 1J9 6-K 1 form6k.htm FORM 6-K Trillium Therapeutics Inc. - Form 6-K - Filed by newsfilecorp.com

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

FORM 6-K

REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 OF THE SECURITIES EXCHANGE ACT OF 1934

For the month of November 2016

Commission File Number: 001-36596

TRILLIUM THERAPEUTICS INC.
(Translation of registrant's name into English)

2488 Dunwin Drive
Mississauga, ON, L5L 1J9
Canada
(Address of principal executive offices)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

Form 20-F [   ]                    Form 40-F [X]

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1)[   ]

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7)[   ]

DOCUMENTS FILED AS PART OF THIS FORM 6-K

See the Exhibit Index hereto.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

  Trillium Therapeutics Inc.
   
   
Date: November 3, 2016
  By: /s/ James Parsons                                         
  Name: James Parsons
  Title: Chief Financial Officer

2

EXHIBIT INDEX

Exhibit Description
   
99.1 News Release dated November 3, 2016

EX-99.1 2 exhibit99-1.htm EXHIBIT 99.1 Trillium Therapeutics Inc.: Exhibit 99.1 - Filed by newsfilecorp.com

FOR IMMEDIATE RELEASE NASDAQ: TRIL
  TSX: TR

TRILLIUM THERAPEUTICS ANNOUNCES INVESTOR AND SCIENTIFIC PRESENTATION
SCHEDULE FOR REMAINDER OF 2016

TORONTO, Nov. 3, 2016 — Trillium Therapeutics Inc. (NASDAQ: TRIL; TSX: TR), a clinical stage immuno-oncology company developing innovative therapies for the treatment of cancer, is scheduled to present an update on the company’s programs and progress at several upcoming conferences in 2016.

Investor Conference:

 • Oppenheimer Life Sciences Summit
  Attendee: Niclas Stiernholm, PhD, Trillium Chief Executive Officer
  Date and Time: Nov. 29, 2016
  Location: Sofitel Hotel, New York City

Scientific Conferences:

 • The Society for Immunotherapy of Cancer (SITC) 31st Annual Meeting
  Presenter: Lisa Johnson, PhD, Trillium Research Scientist
  Title: CD47 is Overexpressed on Merkel Cell Carcinoma and a Target for SIRPαFc Therapy
  Date and Time: Nov. 11, 2016, 12:15 - 1:30 p.m. and 6:15 - 7:30 p.m. ET
  Location: Gaylord National Hotel & Convention Center, National Harbor, MD

 • American Society of Hematology (ASH) 58th Annual Meeting
  Presenter: Stephen Ansell, MD, Division of Hematology, Mayo Clinic
  Title: A Phase 1 Study of TTI-621, a Novel Immune Checkpoint Inhibitor Targeting CD47, in
  Patients with Relapsed or Refractory Hematologic Malignancies
  Session Name: 624. Hodgkin Lymphoma and T/NK Cell Lymphoma - Clinical Studies: Poster I
  Date and Time: Dec. 3, 2016, 5:30 - 7:30 p.m. PT
  Location: San Diego Convention Center, Hall GH, San Diego

1


  Presenter: Zezhou Wang, PhD, Trillium Research Scientist
  Title: TTI-281, an Orally Bioavailable Bromodomain and Extraterminal Domain (BET)
  Inhibitor, Is a Promising Candidate for the Treatment of Multiple Myeloma
  Session Name: 652. Myeloma: Pathophysiology and Pre-Clinical Studies, excluding Therapy:
  Poster I
  Date and Time: Dec. 3, 2016, 5:30 - 7:30 p.m. PT
  Location: San Diego Convention Center, Hall GH, San Diego
   
  Presenter: Jaehyun Choi, PhD, Trillium Research Scientist
  Title: Preclinical Characterization of TTI-281, a Novel, Orally Bioavailable BET Inhibitor:
  Predictive Biomarker Identification and Combination Treatment Analysis
  Session Name: 802. Chemical Biology and Experimental Therapeutics: Poster III
  Date and Time: Dec. 5, 2016, 6:00 - 8:00 p.m. PT
  Location: San Diego Convention Center, Hall GH, San Diego

About Trillium Therapeutics

Trillium Therapeutics Inc. is a clinical stage immuno-oncology company developing innovative therapies for the treatment of cancer. The company’s lead program, SIRPaFc (TTI-621), is a fusion protein that consists of the CD47-binding domain of human SIRPa linked to the Fc region of a human immunoglobulin (IgG1). It is designed to act as a soluble decoy receptor, preventing CD47 from delivering its inhibitory (“do not eat”) signal. Neutralization of the inhibitory CD47 signal enables the activation of macrophage anti-tumor effects by pro-phagocytic (“eat”) signals. A Phase 1 clinical trial (NCT02663518) evaluating SIRPaFc is ongoing in advanced hematologic malignancies, and a second Phase 1 trial is underway in solid tumors (NCT02890368). Trillium also has a proprietary medicinal chemistry platform, using unique fluorine chemistry, which permits the creation of new chemical entities from validated drugs and drug candidates with improved pharmacological properties. Stemming from this platform, the company’s most advanced preclinical program is an orally-available bromodomain inhibitor, followed by an epidermal growth factor receptor antagonist with increased uptake in the brain. In addition, a number of compounds directed at undisclosed immuno-oncology targets are currently in the discovery phase.

For more information visit: www.trilliumtherapeutics.com

Caution Regarding Forward-Looking Information

This press release may contain forward-looking statements, which reflect Trillium’s current expectation regarding future results, events or developments. These forward-looking statements involve risks and uncertainties that may cause actual results, events or developments to be materially different from any future results, events or developments expressed or implied by such forward-looking statements. Such risks and uncertainties are described in the company’s ongoing quarterly and annual reporting. Except as required by applicable securities laws, Trillium undertakes no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.

Neither TSX nor its Regulation Services Provider (as that term is defined in the policies of the TSX) accepts responsibility for the adequacy or accuracy of this release.

Company Contact:
James Parsons
Chief Financial Officer
Trillium Therapeutics Inc.

2

416-595-0627 x232
james@trilliumtherapeutics.com
www.trilliumtherapeutics.com

Investor and Media Relations:
Mark Corbae
Canale Communications for Trillium Therapeutics
619-849-5375
mark@canalecomm.com

 GRAPHIC 3 exhibit99-1x1x1.jpg GRAPHIC begin 644 exhibit99-1x1x1.jpg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